Phase 1 clinical trial parts A and B were achieved successfully with a capsule of lead compound MAP4343 administered to healthy volunteers.
MAPREG lead compound will now be tested in TRD patients, in a a multicentric Proof of Concept Phase 2 trial that is being launched in Q1 2019, involving 10 french hospital centers dedicated to Treatment Resistant Depression. PI of the study is Pr Philippe FOSSATI at La Salpêtrière Hospital, Paris, France.
In parallel MAPREG lead compound will be tested in Alcohol Addiction in a monocentric Proof of Concept Phase 2 trial. PI of the study is Pr Barbara MASON, head of the Scripps Pearson Center Human Research laboratory in Alcohol Addiction, one of the most prominent experts worldwide.
CHU Bicêtre, Batiment Pincus, 80 rue du général Leclerc, 94270 Le Kremlin-Bicêtre, France.